University of Pittsburgh researchers have discovered and characterized a small molecule surrogate, named CZV1-1, for a neutralization epitope on the Zika virus envelope protein. This molecule is the first nonpeptide surrogate and serves as a binding target for human antibodies that bind to a region on domain III of the Zika virus envelope protein. CZV1-1 can be used to develop diagnostic assays with high sensitivity and specificity, especially in populations with high prevalence of dengue antibodies.